New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:17 EDTJNJEarnings Preview: J&J investors will focus on catalysts, operating leverage
Johnson & Johnson (JNJ), a diversified, global healthcare conglomerate, is scheduled to report fourth quarter earnings before the open on Tuesday, January 21, with a conference call scheduled for 8:30 am ET. EXPECTATIONS: Analysts are looking for EPS of $1.20 on revenue of $17.95B, according to First Call. The consensus range for EPS is $1.19-$1.22 on revenue of $17.82B-$18.09B. LAST QUARTER: Johnson & Johnson reported Q3 adjusted EPS of $1.36 against estimates for $1.32 on revenue of $17.6B against estimates for $17.46B. At the time of its Q3 earnings release, J&J also raised its FY13 EPS view to $5.44-$5.49 from $5.40-$5.47. STREET RESEARCH: In a note to investors on January 7, RBC Capital said it expects the company's pharmaceutical franchise to continue to deliver above industry average revenue growth, and it predicts that the company will continue to have operating leverage, enabling its EPS to surpass consensus levels over the next several years. The firm raised its price target on J&J to $104 from $88. On January 10, Barclays downgraded shares of J&J to Equal Weight from Overweight. Barclays downgraded Johnson & Johnson citing limited catalysts and valuation.The firm kept its price target remains $99. PRICE ACTION: Since its last earnings report, shares of J&J are up approximately 5%. Over the last year, shares are up over 30%.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
16:33 EDTJNJGilead submits NDA to FDA for single tablet regimen for HIV containing R/F/TAF
Gilead Sciences (GILD) announced that it has submitted a New Drug Application, or NDA, to the FDA for an investigational, once-daily single tablet regimen that combines Gileadís emtricitabine 200 mg and tenofovir alafenamide, or TAF, 25 mg with rilpivirine 25 mg, or R/F/TAF, from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naÔve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen. A Priority Review voucher acquired from Knight Therapeutics in November 2014 was submitted to the FDA along with the R/F/TAF NDA. Under the Prescription Drug User Fee Act, or PDUFA, the anticipated target action date for the R/F/TAF NDA is six months after the FDAís acceptance of the filing. TAF is a novel, investigational nucleotide reverse transcriptase inhibitor, or NRTI, that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gileadís Viread, as well as improved renal and bone laboratory parameters as compared to TDF in clinical trials in combination with other antiretroviral agents. In addition to R/F/TAF, two other TAF-based HIV treatments are also under FDA review.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use